They just need to get the right people on the BOD and this will fly.
Personally I think it a big mistake to go it alone in the US. unless this is a temporary measure until a suitable distributor is found. Americans do not care to deal with foreign companies in their own back yard and I doubt the VW debacle has helped this sentiment.
Obviously the one they had lined up fell through for whatever reason.
I have held shares 4 longer than I care to remember. But they have only gone down.
Since 2007 Directors have been buying & not 1 sale has been made even on 18/1/2018 they bought 400k & today RBC have rec. outperform target 43p & Peel Hunt target 42p
but they are still down again today.
The CEO is a serial underachiever. Some look at his holding as a positive but he has been drawing a handsome salary and bonus out of this for years. Meanwhile operationally they get everything wrong, after using the cash pile to generate no earnings he is now borrowing. The shares may have halved recently but where is the value in this poorly run company. Taking on more cost and going it alone is another mistake.
Well I've bought some. I assume that EW Healthcare Partners saw some value and agree the amended strategy. The debt may have a high interest rate but it is cheap if saving the company from a right's issue......I've bought some to make me follow the story from now on in....thanks to other BB users for their comments.
All good points, i'd add that previously the sp was probably boosted by potential takeover. I recall that one of the big cosmetics was reportedly interested (I don't think it was L'Oreal, but it was someone similar) but they went elsewhere...
Likewise sitting on a paper loss, however willing to sit tight rather than crystallise it.
For what its worth I thought the move to pure play asthetics was a good one, a growth market if ever there was one in a selfie obsessed world. However, the path has not been smooth and there seems at east one step back for every two forward.
There are many positives in terms of sales growth but several issues.
Thermi distribution and cost of exiting it is a large blot on the landscape.
Its clear they want to discontinue Sculptra but are stuck with a long term distribution deal with Galderma.
Refine delayed for a year due to smoke damage at US facility.
New loan facility looks both expensive and onerous with an interest rate of Euribor +9% and covenants regarding revenue and cash holdings. Clearly the lender thinks there is significant risk..
Share price has halved in the past year and personally sitting on a substantial paper loss but this is not a core holding and content to have this tucked in the bottom drawer with the hope it might come good one day.
Are these results worse than the market was anticipating or is it the go it alone approach in the US which has caused concern? I do not really follow SPH but it appears they've fallen a long way and yet are making positive progress? Any education those with knowledge can provide would be most useful
Not sure what is going on, but from yesterday's performance it looks like the secret is out. And we PIs will have to wait until Monday to find out what that secret is.
My money is on a rights issue. They have probably burned through whatever money they had and still have a lot to spend to get everything up and running. I hope I'm wrong but let's see what Monday brings...
I.M.O. Tosca is not out of the game at all. They sold 5% of Sinclair down to 24.5% but they are now buying again. I think they sold those 5% to a friend, knowing that in case of a major move this friend is going to vote in favor of Toscas proposition. Now they are free to buy up again towards 29%. ...
And here we are: Tosca up to 29% again. Is this the start of the final move...
Could be a last occasion to buy on the cheap.
Nice to see the CEO, his missus and a non exec put some more skin in the game by buying 200K each. CEO now has about 2% of the company. This on the back of a pretty decent trading statement makes me feel quite positive for the future.
Only fly in ointment is the Numis note with a target price of 21p.
Sales increasing across most product lines by healthy percentages and moving to EBITDA profitability and a broker puts out a note with a target price lower then the current price??? What a bunch of monkeys!
RNS: 19/10/2017: New CE mark granted for Silhouette Soft®. Probably what has prompted the move up as people realise that the product has a globally recognised status as an EU approved medical device. Sales should be good on the back of this news. Well done Sinclair from someone who knows a bit about audit of companies who are trying to get (re-get) the CE mark.
I.M.O. Tosca is not out of the game at all. They sold 5% of Sinclair down to 24.5% but they are now buying again. I think they sold those 5% to a friend, knowing that in case of a major move this friend is going to vote in favor of Toscas proposition. Now they are free to buy up again towards 29%.
Another striking coincidence is the SP. Since Sinclair became an aesthetics company and left pharmaceuticals, the SP is quietly mimicking the SP of Almirall (Spain). Have a look at the chart of both Sinclair and Almirall, striking isn't it ?
Anyway, I still expect Sinclair to be taken over rather soon. After all Tosca is probably not going to stay invested in Sinclair for a very long period.
Wonder why the s/p went up 2p today...?
I go all the way back to Medeva years and years ago (please don't remind me how long) then it was I.S. pharma I think,then Sinclair I S Pharma,now Sinclair Pharma....!
Figures maybe out soon perhaps....?
Think as I've been here sooooo long I deserve a return on my investment.Any idea's about how high this share could go anyone....?
shareholding now up to 24%. Will they build to 30% and trigger a bid?
As I understand it they would then have to offer cash to all other shareholders at the highest price they had paid for any shares over the previous 12 months.
Sadly for me that would result is a substantial loss on my purchase price of 63p back when they were Acambis (?), so long ago I can't remember the original incarnation.
Lets hope we see a good SP run up before Tosca get to 30%
Barcelona, 27th February, 2017.- Almirall, the global pharmaceutical company based in Barcelona, has posted its full-year 2016 results today.
2016 has been an important year for Almirall to continue consolidating our new strategic direction. Dermatology continues to be the key growth driver and now accounts for 51% of Net Sales. The addition of Poli Group has reinforced our dermatology Rx business while the acquisition of ThermiGen allows us an entry point into the Aesthetics market.
The acquisition of ThermiGen has been key in Almiralls presence in Aesthetics. 2016 delivered a +62% growth versus the previous year. In 2017 ThermiGen approved devices will be available in the EU.
During 2016, Almirall has continued to transform its business with the ultimate goal of becoming a key player in the global Dermatology market. Poli Group and ThermiGen have been fully integrated within Almirall. In addition, a US distribution and strategic-marketing collaboration agreement was made with Sinclair for Silhouette Instalift, the only injectable aesthetic product with a lifting claim in the US market, providing access for this product to the world's largest Aesthetics market.
Almirall will become a leading specialty pharmaceutical company with a strong focus on improving lives of Dermatology and Aesthetics patients.
The company will use its strong cash position to fund growth opportunities in this direction
Could it be interested in Sinclair as a friendly predator ?
Nice to see a positive move up (7.5%) in anticipation of the final results due out on Tuesday.
This will be almost a full year as a pure play aesthetics company in what is undoubtedly a high potential growth market.
Expecting good news and further positive share price action.
Nestlé Health Science on Feb. 2 said it acquired CM&D Pharma Ltd., a small U.K. company that develops foods for special medical purposes, primarily products for patients with kidney disease, inflammatory bowel disease and colon cancer. CM&D was part of the portfolio of Inventages Group, an independent venture capital fund that Nestlé invests in. Its leading product, Fostrap, is a medical food in the form of a chewing gum for kidney patients who have an elevated level of phosphate in the blood (hyperphosphataemia).
The Wall Street Journal reported CM&D was started in 2007 by former Sinclair Pharma PLC executive Danilo Massari. Though the company has yet to fully launch a product, it has a number of medical foods in trials -- including Eviendep, a mix made from an extract of milk thistle and dietary fiber, which may slow the progression of colon polyps, and Recoclix, a synthetic extract derived from egg yolk, that relieves pain associated with Crohn's disease and inflammatory bowel disease.
"This acquisition is an excellent fit with Nestlé Health Sciences' strategic goal of being a pioneer in the promising area of science-based nutrition," says Luis Cantarell, president/CEO of Nestlé Health Science. "We share CM&D's commitment to use health science for improving the quality of people's lives, and this acquisition will help to reinforce our position in this opportunity. Additionally, CM&D will benefit from Nestlé Health Science's commitment to biomedical research, and the resources of the Nestlé...
Nestlé seems determined to take on its rivals in the dermatology field. A few days ago, Nestlé enrolled Allergan executive Paul Navarre, (president of Allergans international business) to succeed H. Antunes as chief of Nestlé Skin Health. Navarre will bring along plenty of skincare experience to accomplish Nestlé's ambitions. Allergan markets a suite of skin and cosmetic treatments, including the blockbuster wrinkle treatment Botox. Nestlé already has co-marketing rights to Botox rival Dysportl outside the U.S. and Canada, and it also brings to the market several other cosmetic treatments which it bought from Valeant in 2014.
Nestlé intends to diversify beyond the sluggish food business, and it more deals have and probably will follow. For instance, it formed a joint venture with Guthy-Renker, marketer of Proactiv--one of the worlds best-selling acne treatments.
Nestlé has also been a subject of recent rumors concerning Bayers $1.1 billion dermatology business, but the names of other players, including Teva, Almirall and Allergan, seem to be involved in those rumors, too.
You never know Sinclair Pharma comes on their radar as well.
Results initially seemed to be well received, according to the SP at least. Unless I am missing something, most everything appears positive. Sadly SP gains didn't hold. Maybe a few quarters of Sillouette taking Beverley Hills by storm may see things moving in the right direction.
"Sinclairs interim results for the six-month period to 30th June are in line with expectations and the companys trading update in July, with revenue of £17.3m and a strong balance sheet at period-end in spite of significant deferred consideration payments during the period. The potentially transformational US launch of Silhouette Instalift is ongoing since August, backed by ThermiGens 65-strong sales force." - N1 Singer, via Research Tree
Well, there we are. What's not to like - apart from the overhead cost base. All we need now is sales of c£65m and we're in profit! I hope the sales force is good. Mind you, if t/o keeps increasing at 125%pa, it won't take long!
The preliminary announcement in July was well received - as one would expect of a 125% increase in lfl turnover. However, the recent announcement of the departure of Mr Foucher has knocked the shares right back. (I assume that the decline in the share price is for that reason, not some horror in next week's announcement which has been leaked.) Mind you a payoff which is a significant part of the restructuring costs of £2.8m sounds steep, especially in a company with a market cap of £138m. At least he can only leave once - can't he?!!
The shares got a boost when the co. put itself up for sale, its been going on quite a while now so perhaps there isn't buyer... thats my guess and the recent price movement suggests that information is leaking somewhere
Important message from the Financial Conduct Authority:
Posting inside information that is not public knowledge, or information that is false or misleading, may constitute market abuse.
This could lead to an unlimited fine and up to seven years in prison.
If you have any information, concerns or queries about market abuse, click here.
The content of the messages posted represents the opinions of the author, and does not represent the opinions of Interactive Investor Trading Limited or its affiliates and has not been approved or issued by Interactive Investor Trading Limited.
You should be aware that the other participants of the above discussion group are strangers to you and may make statements which may be misleading, deceptive or wrong.
Please remember that the value of investments or income from them may go down as well as up and that the past performance of an investment is not a guide to its performance in the future.
The discussion boards on this site are intended to be an information sharing forum and is not intended to address your particular requirements.
Whilst information provided on them can help with your investment research you need to consider carefully whether you should make (or refraining from making) investment or other decisions based on what you see without doing further research on investments you are interested in.
Participating in this forum cannot be a substitute for obtaining advice from an appropriate expert independent adviser who takes into account your circumstances and specific investment needs in selected investments that are appropriate for you.